Document:

c56842_ex10-1.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

MTM TECHNOLOGIES, INC.

AMENDMENT NO. 6

TO 

AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

     This Amendment No. 6 (this "Amendment No. 6") to the Amended and Restated Registration Rights Agreement dated December
10, 2004, as amended by Amendment No. 1 on November 23, 2005, Amendment No. 2 on March 29, 2007, Amendment No. 3 on April 9, 2007, Amendment No. 4 on May 24, 2007, and Amendment No. 5 on July 25, 2007 (the “Registration Rights Agreement”), among (a) MTM Technologies, Inc., a New York corporation (the "Company"), (b) Steven Rothman, a natural person, (c) Howard Pavony, a natural person (Messrs.
Rothman and Pavony collectively, the “ Executives ”), (d) FirstMark III L.P. and FirstMark III Offshore Partners, L.P., as successors-in-interest to Pequot Private
Equity Fund III, L.P. and Pequot Offshore Private Equity Partners III, L.P., (collectively, the “FirstMark Stockholders”), (e) Constellation Venture Capital II, L.P.,
Constellation Venture Capital Offshore II, L.P., The BSC Employee Fund VI, L.P. and CVC II Partners, LLC (collectively, the “Constellation Stockholders” and together
with the FirstMark Stockholders, the “Investor Stockholders”) is entered into as of February 13, 2009. Capitalized terms used herein and not otherwise defined shall
have the meanings ascribed to such terms in the Registration Rights Agreement. 

Background 

     WHEREAS, the Company has issued Subordinated Promissory Notes (the “Series A-9 Notes”) and Warrants to purchase up to 392,157 shares (as such amount may be adjusted in accordance with
the terms thereof) of the Company’s Series A-9 preferred stock (the “Series A-9 Warrants” and, together with the Series A-9 Notes, the “Series A-9 Agreements”) to the FirstMark Stockholders, dated as of February 28, 2008; 

     
WHEREAS, the Company has issued Subordinated Promissory
Notes (the “Series A-10 Notes”) and Warrants to purchase up
to 733,333 shares (as such amount may be adjusted in accordance with the terms
thereof) of the Company’s Series A-9 preferred stock (the “Series
A-10 Warrants” and,
together with the Series A-10 Notes, the “Series
A-10 Agreements”)
to the FirstMark Stockholders, dated as of June 11, 2008; 

     
WHEREAS, the Company has issued Subordinated Promissory
Notes (the “Series A-11 Notes”) and Warrants to purchase up
to 193,548 shares (as such amount may be adjusted in accordance with the terms
thereof) of the Company’s Series A-11 preferred stock (the “Series
A-11  Warrants” and, together with
the Series A-11 Notes, the “Series A-11
Agreements) to the Investor Stockholders,
dated as of June  16, 2008; 

     
WHEREAS, the Company has issued Subordinated Promissory
Notes (the “Series A-12 Notes”) and Warrants to purchase up
to 137,931 shares (as such amount may be adjusted in accordance with the terms
thereof) of the Company’s Series A-12 preferred stock (the “Series
A-12  Warrants” and, together with
the Series A-12 Notes, the “Series A-12
Agreements,” and
together with the Series A-9 Agreements, the Series A-10 Agreements, and the
Series A-11 Agreements, the “Preferred
Stock Agreements”)
to the FirstMark Stockholders, dated as of February 11, 2009; 

     
WHEREAS, in connection with the Preferred Stock Agreements,
the Investor Stockholders are entering into this Amendment No.
6 in order to amend the Registration Rights Agreement and to provide certain
registration and other rights with respect to the Series A-9 Warrants, the Series
A-10 Warrants, the Series A-11 Warrants and the Series A-12  Warrants; and 

     WHEREAS, pursuant to Section 13(b) of the Registration Rights Agreement, this Amendment No. 6 requires the consent of the Company, a Pequot Majority in Interest and a Constellation Majority in
Interest. 

NOW, THEREFORE, in consideration of the mutual promises and agreements contained herein, and intending to be legally bound hereby, the parties hereto agree as follows: 

	
1.        	
Amendments.  
	 
	 	
(a)        	
The following new recitals shall be added after the tenth recital to the Registration Rights Agreement as follows:  
	 
	 	 	
WHEREAS, in connection with the issuance of Subordinated Promissory Notes (the “Series A-9 Notes”) to FirstMark III L.P. and FirstMark III Offshore Partners, L.P., as successors-in-interest to Pequot Private
Equity Fund III, L.P. and Pequot Offshore Private Equity Partners III, L.P. (collectively, the “FirstMark Stockholders ”), dated as of February 28, 2008, the Company
issued warrants to purchase up to 392,157 shares (as such amount may be adjusted in accordance with the terms thereof) of the Company’s Series A-9 Preferred Stock (the “Series A-9
Warrants” and, together with the Series A-9 Notes, the “Series A-9 Agreements”) to the FirstMark Stockholders;  
	 

	 	 	WHEREAS, in connection
          with the issuance of Subordinated Promissory Notes (the “Series
          A-10 Notes”) to the FirstMark Stockholders, dated as of June 11,
          2008, the Company issued warrants to purchase up to 733,333 shares
          (as such amount may be adjusted in accordance with the terms thereof)
          of the Company’s Series A-10 Preferred Stock (the “Series
          A-10 Warrants” and, together
          with the Series A-10 Notes, the “Series A-10 Agreements”)
          to the FirstMark Stockholders; 

       WHEREAS, in connection with
          the issuance of Subordinated Promissory Notes (the “Series A-11
          Notes”) to the FirstMark Stockholders and Constellation Venture
          Capital II, L.P., Constellation Venture Capital Offshore II, L.P.,
          The BSC Employee Fund VI, L.P. and CVC II Partners, LLC (collectively,
          the “ Constellation Stockholders”),
          dated as of June 16, 2008, the Company issued warrants to purchase
          up to 193,548 shares (as such amount may be adjusted in accordance
          with the terms thereof) of the Company’s Series A-11 Preferred
          Stock (the “Series A-11 Warrants” and,
          together with the Series A-11 Notes, the “Series A-11 Agreements”)
          to the FirstMark Stockholders and the Constellation Stockholders; 

       WHEREAS, in connection with
          the issuance of Subordinated Promissory Notes (the “Series A-12
          Notes”) to the FirstMark Stockholders, dated as of February 11,
          2009, the Company issued warrants to purchase up to 137,931 shares
          (as such amount may be adjusted in accordance with the terms thereof)
          of the Company’s Series A-12 Preferred Stock (the “Series
          A-12 Warrants”
          and, together with the Series A-12 Notes, the “Series A-12 Agreements” and,
          together with the Series A-9 Agreements, the Series A-10 Agreement
          and the Series A-11 Agreements, the “Preferred Stock Agreements”); 

       WHEREAS, in connection with
          the transactions contemplated by the Preferred Stock Agreements, the
          Company and the Investor Stockholders are entering into this Amendment
          No. 6, in order to amend the Registration Rights Agreement and to provide
          certain registration and other rights with respect to the Common Stock
          held by or issuable to the Investor Stockholders pursuant to the Preferred
    Stock Agreements; 

(c) The following definitions in Section 1 of the Registration
Rights Agreement shall be amended in their entirety and replaced
with the following:

	      	
(i)        	
“Investor Stockholders.” The FirstMark Stockholders and the Constellation Stockholders.  
	 
	 	
(iv)        	
“Series A Preferred Stock.” The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series A-5 Preferred Stock, Series A-6 Preferred Stock, Series A-7
Preferred Stock, Series A-8 Preferred Stock, Series A-9 Preferred Stock, Series A-10 Preferred Stock, Series A-11 Preferred Stock, and Series A-12 Preferred Stock, collectively.  
	 
	 	
(v)        	
“Shares.” All shares of Series A Preferred Stock issued to the Investor Stockholders, including those issued in accordance with the Initial Series A Purchase Agreement, the Purchase Agreement, the Series A-6
Purchase Agreement, the Series A-7 Purchase Agreement, the Series A-8 Purchase Agreement, the Series A-9 Agreements, the Series A-10 Agreements, the Series A-11 Agreements and the Series A-12 Agreements.  
	 
	 	
(vi)        	
“Warrants.” The Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, Series A-4 Warrants, the Series A-5 Warrants, the Series A-6 Warrants, the Series A-7 Warrants, the Series A-8 Warrants, the Series A
- 9 Warrants, the Series A-10 Warrants, the Series A-11 Warrants and the Series A-12 Warrants issued to the Investor Stockholders.  
	 

	
(d)        	
The following definitions shall be added in alphabetical order to Section 1 of the Registration Rights Agreement:  
	 
	 	
(i)        	
“FirstMark Stockholders.” FirstMark III L.P. and FirstMark III Offshore Partners, L.P., as successors-in- interest to Pequot Private Equity Fund III, L.P. and Pequot Offshore Private Equity Partners III,
L.P.  
	 
	 	
(ii)        	
“FirstMark Majority in Interest.” The FirstMark Stockholders holding at least a majority of the shares of Common Stock issued or issuable, directly or indirectly, upon conversion or exercise of the Shares and
Warrants purchased by such FirstMark Stockholders in accordance with the Initial Series A Purchase Agreement, the Purchase Agreement, the Series A-6 Purchase Agreement, the Series A-7 Purchase Agreement, the Series A-8 Purchase Agreement, the Series
A-9 Agreements, the Series A-10 Agreements, the Series A-11 Agreements and the Series A-12 Agreements.  
	 
	 	
(iii)        	
“Series A-9 Preferred Stock” The Series A-9 Preferred Stock of the Company, par value $.001 per share.  
	 

	      	
(vii)        	
“Series A-9 Warrants” as defined in the recitals to this Amendment No. 6.  
	 
	 	
(iv)        	
“Series A-10 Preferred Stock” The Series A-10 Preferred Stock of the Company, par value $.001 per share.  
	 
	 	
(viii)        	
“Series A-10 Warrants” as defined in the recitals to this Amendment No. 6.  
	 
	 	
(v)        	
“Series A-11 Preferred Stock” The Series A-11 Preferred Stock of the Company, par value $.001 per share.  
	 
	 	
(ix)        	
“Series A-11 Warrants” as defined in the recitals to this Amendment No. 6.  
	 
	 	
(vi)        	
“Series A-12 Preferred Stock” The Series A-12 Preferred Stock of the Company, par value $.001 per share.  
	 
	 	
(x)        	
“Series A-12 Warrants” as defined in the recitals to this Amendment No. 6.  
	 
	 	 	
(e) The following definitions shall be deleted in their entirety from Section 1 of the Registration Rights Agreement:  
	 
	 	
(i)        	
“Pequot Stockholders.”  
	 
	 	
(ii)        	
“Pequot Majority in Interest.”  
	 

	
2.        	
Entire Agreement. This Amendment No. 6 and the Registration Rights Agreement are to be read together as one instrument. The Registration Rights Agreement shall remain in full force
and effect, except as modified hereby.  
	 
	
3.        	
Governing Law. This Amendment No. 6 is made pursuant to, and shall be governed by and construed in accordance with, the laws of the State of New York, other than provisions thereof
relating to conflicts of law.  
	 
	
4.        	
Counterparts. This Amendment No. 6 may be executed in any number of counterparts, each of which shall be considered an original and which shall together constitute one
instrument.  
	 
	
5.        	
Headings. The titles and subtitles used in this Amendment No. 6 are used for convenience only and are not to be considered in construing or interpreting this Amendment No.
6.  
	 

[Remainder of this page intentionally blank]

     
IN WITNESS WHEREOF, the parties have executed this Amendment No. 6 as of the date first above written.

 

	 	COMPANY: 
	 	 	 	 
	 	MTM TECHNOLOGIES, INC.
	 	 	 	 
	 	 	By: 	/s/ Steven Stringer 
	 	 	 	Name: Steve Stringer 

      Title: President and CEO
	 	 	 	 
	 	PEQUOT STOCKHOLDERS:
	 	 	 	 
	 	FIRSTMARK III L.P. 
	 	 	 	 
	 	By:  	FirstMark Capital, L.L.C. its Investment
    Manager  
	 	 	 	 
	 	 	By:  	/s/
    Gerald A. Poch 
	 	 	 	Name: Gerald A. Poch

    Title: Chairman and Managing Director
	 	 	 	 
	 	FIRSTMARK III OFFSHORE PARTNERS,
    L.P.
	 	 	 	 
	 	By:  	FirstMark Capital, L.L.C.
    its Investment Manager  
	 	 	 	 
	 	 	By:  	/s/
    Gerald A. Poch 
	 	 	 	Name: Gerald A. Poch

    Title: Chairman and Managing Director
	 	 	 	 
	 	CONSTELLATION STOCKHOLDERS: 
	 	 	 	 
	 	CONSTELLATION VENTURE CAPITAL 
      II, L.P. 
	 	 	 	 
	 	By: 	Constellation Ventures
    Management II, LLC, 

    Its General Partner
	 	 	 	 
	 	 	 	/s/
    Tom Wasserman
	 	 	 	Name: Tom
        Wasserman

     Title: Managing
    Director
	 	 	 	 

 

 

	 	CONSTELLATION VENTURE
    CAPITAL OFFSHORE II, L.P.: 
	 	 	 	 
	 	By: 	Constellation Ventures
    Management II, 

    LLC, Its General Partner  
	 	 	 	 
	 	 	By: 	/s/
        Tom Wasserman
	 	 	 	Name: Tom Wasserman

      Title: Managing Director
	 	 	 	 
	 	THE BSC EMPLOYEE FUND
    VI, L.P.
	 	 	 	 
	 	By: 	Constellation
    Ventures Management II, 

    LLC, Its General Partner  
	 	 	 	 
	 	 	By: 	/s/
        Tom Wasserman
	 	 	 	Name: Tom Wasserman

      Title: Managing Director
	 	 	 	 
	 	CVC II PARTNERS, LLC
	 	 	 	 
	 	By: 	The Bear Stearns Companies Inc., 

    Its Managing Member
	 	 	 	 
	 	 	By: 	/s/
        Tom Wasserman
	 	 	 	Name: Tom Wasserman

      Title: Managing Directorexv10w8

Exhibit 10.8

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION

OMEPRAZOLE SUPPLY AGREEMENT

AMENDMENT NO. 3

     This Amendment (the “Amendment”) by and among Santarus, Inc., a Delaware corporation
having a principal place of business at 3721 Valley Centre Drive, Suite 400, San Diego, CA 92130
(“SANTARUS”), Interchem Trading Corporation d/b/a Interchem Corporation, a New Jersey corporation
located at 120 Route 17 North, Paramus, New Jersey 07652 (“INTERCHEM”), and Union Quimico
Farmaceutica, S.A., a corporation of Spain located at Mallorca, 262, 08008, Barcelona, Spain
(“UQUIFA”) is entered into as of December 17, 2008 (the “Effective Date”).

     Whereas, SANTARUS, INTERCHEM and UQUIFA have entered into that certain Omeprazole
Supply Agreement, dated September 25, 2003, as amended (the “Agreement”), wherein UQUIFA agrees to
manufacture and supply Omeprazole to SANTARUS;

     Whereas, Section 5.3 of the Agreement provides that the price for the Omeprazole to
be purchased by SANTARUS under the Agreement shall be renegotiated by SANTARUS, on the one hand,
and INTERCHEM and UQUIFA, on the other hand, in good faith on [***] at a mutually agreed upon time
and reasonably in advance of the expiration of the applicable [***] period and taking into account
then prevailing market conditions; and

     Whereas, SANTARUS, INTERCHEM and UQUIFA desire to amend and restate Schedule C of the
Agreement pursuant to and in accordance with Section 5.3 in order to set a new price for the
Omeprazole to be purchased by SANTARUS under the Agreement and to clarify the timing for future
price adjustments.

     Now, Therefore, in consideration of the foregoing recitals and the mutual agreements
contained in this Amendment, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, SANTARUS, INTERCHEM and UQUIFA, intending to be
legally bound hereby, agree as follows:

     1. Schedule C of the Agreement is hereby amended and restated in its entirety to read as
follows:

“SCHEDULE C

PRICING AND SHIPPING TERMS

Freight Terms: INTERCHEM and UQUIFA shall make all necessary shipping arrangements to SANTARUS’
designated facility, [***]
SANTARUS’ designated facility, freight prepaid.

Shipping Method: Air Freight

Price: [***]

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

     2. It is hereby acknowledged that in accordance with Section 11.1 of the Agreement, the
Agreement has automatically renewed for an additional two (2) years and shall be effective until
September 25, 2011.

     3. Except as specifically set forth herein, all of the terms and provisions of the Agreement
shall remain unchanged, unmodified and in full force and effect, and the Agreement shall be read
together and construed with this Amendment.

     4. Capitalized terms used but not otherwise defined herein shall have the meanings assigned to
such terms in the Agreement.

     5. This Amendment may be executed in any number of counterparts, all of which taken
together shall constitute one and the same instrument and any of the parties hereto may execute
this Amendment by signing any such counterpart.

     In Witness Whereof, the parties hereto have caused this Amendment to be executed as
of the date first above written.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Santarus, Inc.,

a Delaware corporation	 	 	 	Interchem Trading Corporation

d/b/a Interchem Corporation,

a New Jersey corporation	 	 
 
 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Warren Hall	 	 	 	By:	 	/s/ Ronald J. Mannino	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Warren Hall
	 	 	 	 	 	Name:
	 	Ronald J. Mannino	 	 
	 	 	Title:	 	Senior Vice President, Product

Development and Manufacturing	 	 	 	Title:	 	Chairman	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Union Quimico Farmaceutica, S.A.,

a corporation of Spain	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Mark Ian Robbins	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Mark Ian Robbins	 	 	 	 	 	 	 	 	 	 
	 

	 	Title:
	 	Chief Executive

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]